Infant Formula With Beta-Palmitate Promotes Well-Being

KFAR BARUCH, IsraelEnzymotec will publish four new scientific articles on its lipid-based ingredients for infant nutrition in peer-reviewed journals in the coming months. The large-scale clinical research trials were conducted on newborn term infants in several institutes worldwide and the positive results already have been presented at leading professional conferences.

One recently completed study was a controlled clinical trial on InFat®, a beta-palmitate ingredient that successfully mimics the fat composition and properties of human milk fat. It enables easy digestion and optimized uptake of calcium, fat recovery and energy. InFat is marketed by Advanced Lipids, a joint venture of AAK and Enzymotec. The study was the first testing the positive effect of a commercial infant formula containing beta-palmitate on Chinese infants well-being. It was conducted by researchers at Sun Yat-Sen University in collaboration with Enzymotec.

The clinical trials plan represents Enzymotecs ongoing commitment to explore the special characteristics of human milk and demonstrate its lipid-based ingredients health benefits on various infant populations," said Yael Lifshitz, PhD, Director of R&D, of Enzymotec Infant Nutrition.